Melanoma 2016 — the Year in Review

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 20 January 2017 In News

In the nearly 10 years since MRA’s founding in 2007, there has been extraordinary progress for melanoma. With 11 new treatments approved since 2011, it began to feel like frequent new drug approvals was the current norm.

Read More

Understanding Neoantigens: A Critical Target for Improving Immunotherapy

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 20 January 2017

The approval of eleven new therapies for melanoma since 2011 has led to dramatic changes in how doctors treat melanoma and even more importantly, has led to better outcomes for many patients. Chief among the new therapies are those that target the immune system.

Read More

Melanoma Immunotherapy and Precision Medicine — a Medical Student’s Perspective

By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 20 January 2017 In Science

Malignant melanoma research has provided the perfect opportunity to explore the intersection of immunotherapy and precision medicine, which has greatly transformed melanoma therapeutics in the last decade.

Read More

Tara's Story

By Pamela Goldsmith, MRA Director of Communications | 20 January 2017 In Melanoma Stories

To say that Tara Miller inspired mixed emotions is to begin to understand her life. The strong-willed survivor, who lost her battle to melanoma in 2014, reflected the contradictions that define an indomitable will to live.

Read More

Parallels between Disease States

By Michael Kaplan, MRA President & CEO | 30 November 2016 In Science

Six months ago I was offered the opportunity to serve as President & CEO of MRA and in July, I officially began. For the past 24 years, I’ve worked in the HIV field and am struck by the many parallels that exist between my past work and melanoma.

Read More

Uncommon Immunotherapy Side Effects

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 November 2016

A recent report in the prestigious New England Journal of Medicine (NEJM), has spawned reports like this one, regarding the risk of death in patients treated with combination checkpoint treatments. The first author of the NEJM story is MRA-funded investigator, Doug Johnson at Vanderbilt.

Read More

Championing Collaboration

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 November 2016

Some have the impression that cancer researchers, whether in academia or in industry, toil away in isolation. While there are certainly scientists who work best on their own, collaboration among researchers has become increasingly common, with a goal of achieving the most promising results in the shortest time frame.

Read More

MRA Funded Melanoma Researchers Led Discussions at 2016 Annual Meeting of the Society for Immunotherapy of Cancer

By Pamela Goldsmith, MRA Director of Communications | 30 November 2016

MRA Director of Communications Melanoma Research Alliance (MRA) investigators and other melanoma researchers had a significant presence at this year’s annual meeting of the Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. A key forum for scientific exchange and enlightenment in the cancer immunotherapy field, the conference...

Read More

To Screen or Not to Screen (for Skin Cancer) – Reframing the Question

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 29 July 2016

To screen or not to screen actually isn’t the question  While an adaptation of Hamlet’s famous phrase may capture the headlines on whole-body skin checks, a deeper dive gets us closer to questions of life and death.

Read More